Table 3.

Predictors of the percentage change in adiponectin in response to ER niacin/laropiprant.

Variables	% change in adiponectin
	Univariate analysis		Multivariate analysis
	r	P	r	P
Age, years	0.197	0.03	0.088	0.353
Gender (1 = male, 2 = female)	0.228	0.012	0.215	0.006
Baseline body weight, kg	−0.387	<0.001	0.068	0.475
Baseline body fat, %	−0.135	0.139
Baseline body fat mass, kg	−0.351	<0.001	−0.265	0.001
Baseline BMI, kg/m2	−0.389	<0.001	−0.003	0.972
Baseline waist circumference, cm	−0.421	<0.001	−0.04	0.672
Hypertension (1 = Yes, 2 = No)	0.273	0.002	0.207	0.008
Diabetes (1 = Yes, 2 = No)	−0.007	0.938
Baseline adiponectin levels, µg/mL	0.043	0.637
Baseline glucose levels, mmol/L	−0.063	0.493
Baseline insulin levels, mU/L	−0.272	0.003	−0.073	0.44
Baseline HOMA-IR	−0.276	0.002	0.061	0.516
% change in body weight	−0.078	0.396
% change in body fat mass	−0.235	0.01	−0.238	0.003
% change in lean body mass	0.14	0.126
% change in fasting glucose	0.221	0.015	0.189	0.015
% change in HbA1c	0.045	0.624
% change in insulin	0.184	0.043	∗
% change in HOMA-IR	0.237	0.009	0.037	0.697
% change in FFA	0.083	0.364
% change in HDL-C	0.121	0.186
% change in triglycerides	−0.303	<0.001	−0.176	0.027
% change in LDL-C	−0.256	0.005	−0.105	0.268

^∗Not included due to collinearity with % change in HOMA-IR.

BMI: body mass index; FFA: free fatty acids; HbA1C: glycated haemoglobin; HDL-C: high-density lipoprotein cholesterol; HOMA-IR: Homeostasis Model of Assessment-Insulin Resistance; LDL-C: low-density lipoprotein cholesterol.